Abstract
Background
Atypical haemolytic uraemic syndrome (aHUS) is caused by dysregulated complement activation. A humanised anti-C5 monoclonal antibody has recently become available for treatment of this condition
Case-Diagnosis/Treatment
We present the first description of an infant with an activating mutation of complement factor B successfully treated with eculizumab. On standard doses she had evidence of ongoing C5 cleavage despite a good clinical response.
Conclusions
Eculizumab is effective therapy for aHUS associated with factor B mutations, but recommended doses may not be adequate for all patients.
This is a preview of subscription content, log in via an institution to check access.
References
Loirat C, Frémeaux-Bacchi V (2011) Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 6:60
Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJH (2010) Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 31:E1445–E1460
Bexborn F, Andersson PO, Chen H, Nilsson B, Nilsson Ekdahl K (2008) The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb). Mol Immunol 45:2370–2379
Joiner KA (1988) Complement evasion by bacteria and parasites. Annu Rev Microbiol 42:201–230
Ricklin D (2012) Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy. Immunobiology 217:1057–1066
de Jorge EG, Harris C, Esparza-Gordillo J, Carreras L, Arranz EA, Abarrategul G, López-Trascasa M, Sánchez-Corral P, Morgan BP, de Córdoba SR (2007) Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA 104:240–245
Besbas N, Gulhan B, Karpman D, Topaloglu R, Duzova A, Korkmaz E, Ozaltin F (2013) Neonatal onset hemolytic uremic syndrome successfully treated with eculizumab. Pediatr Nephrol 28:155–158
Cavci FS, Cakar N, Hancer VS, Uncu N, Acar B, Gur G (2012) Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation. Pediatr Nephrol 27:2327–2331
Al-Akash SL, Almond PS, Savill VH Jr, Gharaybey SL, Hogue C (2011) Eculizumab induces long-term remission in recurrent post transplant HUS associated with C3 gene mutation. Pediatr Nephrol 26:613–619
Châtelet V, Lobbedez T, Frémeaux-Bacchi V, Ficheux M, Ryckelynck JP, Hurault de Ligny B (2010) Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report. Transplant Proc 42:4353–4355
Salem G, Flynn J, Cataland SR (2013) Profound neurological injury in a patient with atypical hemolytic uremic syndrome. Ann Hematol 92:557–558
Malina M, Gulati A, Bagga A, Majid MA, Simkova E, Schaefer F (2013) Peripheral gangrene in children with atypical hemolytic uremic syndrome. Pediatrics 131:e331–e335
Acknowledgements
Drs. MR Haq, A Nagra and MJ Harmer are thanked for their clinical contributions.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gilbert, R.D., Fowler, D.J., Angus, E. et al. Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B. Pediatr Nephrol 28, 1315–1318 (2013). https://doi.org/10.1007/s00467-013-2492-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-013-2492-x